Targeting NF-κB-mediated inflammatory pathways in cisplatin-resistant NSCLC.

@article{Ryan2019TargetingNI,
  title={Targeting NF-$\kappa$B-mediated inflammatory pathways in cisplatin-resistant NSCLC.},
  author={Sarah-Louise Ryan and Sam Beard and Martin P. Barr and Kazou Umezawa and Susan Heavey and Peter Godwin and Steven G. Gray and David Cormican and Stephen P. Finn and Kathy Gately and Anthony Davies and Erik W. Thompson and Derek J Richard and Kenneth J. O'Byrne and Mark N. Adams and Anne-Marie Baird},
  journal={Lung cancer},
  year={2019},
  volume={135},
  pages={
          217-227
        }
}
View on PubMed
discovery.ucl.ac.uk
8 Citations
Highly Influential Citations
1
Background Citations
3
Methods Citations
2

8 Citations

Citation Type

Citation Type

Identification of Proteins Deregulated by Platinum-Based Chemotherapy as Novel Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer
TLDR
This study identified novel biomarkers and/or druggable proteins from deregulated protein networks within non-oncogene driven disease that are involved in the cellular response to cisplatin in NSCLC.
Defining COMMD4 as an anti-cancer therapeutic target and prognostic factor in non-small cell lung cancer
TLDR
Investigating the prognostic and therapeutic potential of the copper-metabolism-domain-protein, COMMD4, in non-small cell lung cancers indicated that it may function as a prognostic factor and a potential therapeutic target for NSCLC, as its depletion induces cancer cell death.
Exosomal ERp44 derived from ER-stressed cells strengthens cisplatin resistance of nasopharyngeal carcinoma
TLDR
The data suggested that exosomal ERp44 derived from ER-stressed NPC cells took an inevitable role in NPC chemoresistance and might act as a treatment target.
H3K27me3 conditions chemotolerance in triple-negative breast cancer.
TLDR
By monitoring epigenomes, transcriptomes and lineages with single-cell resolution, it is shown that the repressive histone mark H3K27me3 (trimethylation of histone H3 at lysine 27) regulates cell fate at the onset of chemotherapy, which highlights how chromatin landscapes shape the potential of cancer cells to respond to initial therapy.
Understanding Lung Carcinogenesis from a Morphostatic Perspective: Prevention and Therapeutic Potential of Phytochemicals for Targeting Cancer Stem Cells
TLDR
A comprehensive overview of how normal lung tissue operates and relate it with lung carcinogenesis to redefine better targets for lung cancer stem cells is provided and it is proposed that lung carcinomas should be treated differently based on their respective cellular origins.
Macrophages Reduce the Sensitivity of Osteosarcoma to Neoadjuvant Chemotherapy Drugs by Secreting Interleukin-1 Beta.
New tricks of old drugs: Repurposing non-chemo drugs and dietary phytochemicals as adjuvants in anti-tumor therapies.
RSF1 in cancer: interactions and functions
TLDR
The functional domains of RSF1 are summarized, the overexpression status ofRSF1 and SNF2H in cancer based on the TCGA and GTE X databases, the cancer-related functions of RSf1 in interacting with H2Aub, HDAC1, CENP-A, PLK1, ATM, C ENP-S, SNF 2H, HB X and NF-κB are summarized and the potential clinical value is summarized.

References

SHOWING 1-10 OF 132 REFERENCES
Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC
TLDR
The data demonstrate the existence of a lung CSC population and suggest a role for targeting ALDH1 as a potential therapeutic strategy in re-sensitizing NSCLC cells to the cytotoxic effects of cisplatin.
Generation and Characterisation of Cisplatin-Resistant Non-Small Cell Lung Cancer Cell Lines Displaying a Stem-Like Signature
TLDR
Characterisation studies demonstrated a decreased proliferative capacity of lung tumour cells in response to cisplatin, increased resistance to cisPlatin-induced cell death, accumulation of resistant cells in the G0/G1 phase of the cell cycle and enhanced clonogenic survival ability.
Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
Triggering TLR3 pathway promotes tumor growth and cisplatin resistance in head and neck cancer cells.
Down-regulation of NF kappa B activation is an effective therapeutic modality in acquired platinum-resistant bladder cancer
TLDR
There was a distinct change in the activation level of NF-κB between T24 and T24PR cells, suggesting strong nuclear localization of NF -κB could be a promising target after developing acquired platinum-resistance in bladder cancer.
Involvement of NF-κB activation in the cisplatin resistance of human epidermoid carcinoma KCP-4 cells.
TLDR
The results suggest that the high cisplatin resistance of KCP-4 cells compared with KB-3-1 cells results from multiple mechanisms other than increased cis platin efflux, including the activation of NF-κB.
Key Players of Cisplatin Resistance: Towards a Systems Pharmacology Approach
TLDR
HRas, p38, CCL2, DOK1, PTK2B and JNK3 were integrated into a model of resistance-associated signalling alterations describing differential gene and protein expression between cisplatin-sensitive and -resistant cells in reaction to cisplatoon exposure.
Inhibition of NF-kappaB sensitizes non-small cell lung cancer cells to chemotherapy-induced apoptosis.
The combination therapy of HIF1α inhibitor LW6 and cisplatin plays an effective role on anti-tumor function in A549 cells.
TLDR
It is revealed that hypoxia-improved cisplatin chemoresistance of NSCLC cells by regulated MDR1 and MRP1 expression via HIF1α/ROS pathway is reversed by LW6, suggesting that LW6 may act as effective sensitizer in chemotherapy forNSCLC.
The combination therapy of HIF1α inhibitor LW6 and cisplatin plays an effective role on anti-tumor function in A549 cells.
TLDR
It is revealed that hypoxia-improved cisplatin chemoresistance of NSCLC cells by regulated MDR1 and MRP1 expression via HIF1α/ROS pathway is reversed by LW6, suggesting that LW6 may act as effective sensitizer in chemotherapy forNSCLC.
...
1
2
3
4
5
...